Cite
HARVARD Citation
Geng, N. et al. (2021). The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen. Technology in cancer research & treatment. p. . [Online].